688 results on '"Sekine, Ikuo"'
Search Results
2. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
3. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database
4. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors
5. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation
6. Echocardiography image quality of global longitudinal strain in cardio-oncology: a prospective real-world investigation
7. Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
8. Real world data are needed to establish safety of adjuvant immune checkpoint inhibitors after pneumonectomy
9. Clinical development of immune checkpoint inhibitors in Japan—the same goal, different paths
10. Locally Advanced Non-small Cell Lung Cancer and Targeted Therapy
11. Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
12. High-Performance Liquid Chromatography for Therapeutic Drug Monitoring of Serum Lenvatinib
13. Clonal heamatopoiesis and associated cardiovascular diseases
14. Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer
15. Retrospective analysis of lung cancer patients treated with supportive care alone
16. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens
17. GL2-5 Criteria for treatment efficacy, analgesics, RI therapy, rehabilitation, and nursing
18. A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer
19. Immune checkpoint inhibitor-related myocarditis
20. Cardiovascular toxic effects of targeted cancer therapy
21. Clinical Trials for Lung Cancer in Progress in Japan
22. Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events
23. Replication-competent adenoviruses with the type 35-derived fiber-knob region achieve reactive oxygen species-dependent cytotoxicity and produce greater toxicity than those with the type 5-derived region in pancreatic carcinoma
24. A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene
25. A combinatory use of adenoviruses expressing melanoma differentiation-associated gene-7 and replication-competent adenoviruses produces synergistic effects on pancreatic carcinoma cells
26. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
27. Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer
28. Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
29. Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients
30. Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin Followed by Pemetrexed Consolidation Therapy in Japanese Patients With Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
31. Case reports of adverse drug reactions associated with nivolumab administration
32. Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report
33. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab
34. Phase I Study of Concurrent High-Dose Three-Dimensional Conformal Radiotherapy With Chemotherapy Using Cisplatin and Vinorelbine for Unresectable Stage III Non-Small-Cell Lung Cancer
35. Retrospective Analysis of Third-Line and Fourth-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer
36. Characteristics of Cancers in Adolescents and Young Adults Compared with Those in Adults in Their 60s: A Single-Center Experience
37. Outcomes of first-line osimertinib treatment for epidermal growth factor receptor-mutated non-small cell lung cancer in clinical practice settings
38. Salvage Photon or Proton Radiotherapy for Oligo-recurrence in Regional Lymph Nodes After Surgery for Non-small Cell Lung Cancer
39. Genetic variations of orosomucoid genes associated with serum alpha‐1‐acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer
40. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer
41. Squamous Cell Carcinoma of Unknown Primary: Multiple Skeletal Metastases Without Detectable Visceral Lesions
42. Analysis of the Association Between Low Dose Bone, Lung, and Heart Irradiation and Survival Rates for Patients Who Received High-dose Proton Beam Therapy With Concurrent Chemotherapy for Stage III Non-small Cell Lung Cancer
43. Comparative Chemotherapeutic Efficacy in Non-small Cell Lung Cancer Patients with Postoperative Recurrence and Stage IV Disease
44. Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel
45. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
46. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy
47. Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses
48. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
49. Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry)
50. Long‐term outcomes of high‐dose (74GyE) proton beam therapy with concurrent chemotherapy for stageIIInonsmall‐cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.